Compare Inovio Pharmaceuticals Inc (INO) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Global X Defense Tech ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Global X Defense Tech ETF trades at $59.83 (market cap $6.29B). The key difference: Global X Defense Tech ETF is far larger — about 56.1× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Global X Defense Tech ETF for 44 Days on average.
| INO | SHLD | |
|---|---|---|
Market Cap | $112.19M | $6.29B |
Volume | 3,201,278 | 1,133,252 |
Sector | Health | Sector/Thematic |
52-Week High | $2.65 | $78.02 |
52-Week Low | $0.66 | $58.20 |
Typical Hold Time | 43 Days | 44 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
SHLD, the Global X Defense Tech ETF, trades at $58.74, down 2.2% on the day amid a bearish technical signal. The ETF focuses on defense technology and cybersecurity, with recent institutional buying interest noted in filings. However, key financial ratios like P/E and P/S are not available for this ETF, and the overall technical picture is negative, with moving averages and oscillators signaling bearish momentum.
The outlook for SHLD is mixed, with potential tailwinds from rising global defense spending and institutional accumulation, but weighed down by bearish technicals and the absence of clear valuation metrics. Risks include geopolitical shifts and ETF-specific performance versus peers. The investment case hinges on sustained defense budget growth and SHLD's ability to capture tech-driven defense innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
